# Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

> **NCT04441385** · PHASE2 · TERMINATED · sponsor: **Hospital Universitario Infanta Leonor** · enrollment: 60 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Maraviroc 300 mg
- **OTHER:** Standard care therapy

## Key facts

- **NCT ID:** NCT04441385
- **Lead sponsor:** Hospital Universitario Infanta Leonor
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-26
- **Primary completion:** 2021-02-08
- **Final completion:** 2021-02-08
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** lack of viability
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441385, "Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04441385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*